MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced ...

SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and patients, today reported data from its pivotal ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT ®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U ...

Medtronic's proposed acquisition of Intersect ENT raised some eyebrows at the Federal Trade Commission. The FTC ordered Medtronic to divest Intersect's Fiagon business within 10 days of the ...

Intersect ENT XENT reported first-quarter 2022 GAAP loss per share of 85 cents, wider than the year-ago adjusted loss of 61 cents. The figure was also wider than the year-ago adjusted loss of 34 cents ...

Intersect ENT Inc., of Menlo Park, Calif., picked up Fiagon AG Medical Technologies less than two years ago in a bid to expand its footprint in the ear/nose/throat (ENT) business, but that acquisition ...

A month has gone by since the last earnings report for Intersect ENT (XENT). Shares have added about 17.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

On May 13, 2022, Medtronic, Inc. announced that it completed the acquisition of Intersect ENT, Inc. The transaction was only able to gain approval of the Federal Trade Commission (FTC) upon the ...

Medtronic and Intersect ENT struck a deal in August 2021 that would bring the rhinosinusitis device developer under the Medtronic umbrella for a total of $1.1 billion in cash. ((Wikimedia Commons)) ...